Please join this four part streaming series starting:
- Wednesday, March 10, 2021 at 12 Noon US Central Time
- New therapies of tardive dyskinesia
- Wednesday, March 24, 2021 at 12 Noon US Central Time
- Gene-based therapies in Huntington's disease
- Wednesday, April 7, 2021 at 12 Noon US Central Time
- New therapies of OFF time in Parkinson's disease – Presented in both Spanish and English
- Wednesday, April 21, 2021 at 12 Noon US Central Time
- Investigational disease-modifying therapies in Parkinson’s Disease
Carlos Singer, MD; University of Miami Miller School of Medicine; Miami, FL, USA
Tiago A. Mestre, MD, MSc; University of Ottawa; Ottawa, ON, Canada
Joseph H. Friedman, MD; Butler Hospital and Warren Alpert Medical School of Brown University; Providence, RI, USA
Stewart A. Factor, DO; Emory University School of Medicine; Atlanta, GA, USA
Mark Guttman, MD, FRCPC; University of Toronto; Toronto, ON, Canada
Claudia M. Testa, MD, PhD; Virginia Commonwealth University; Richmond, VA, USA
Mayela Rodriguez Violante, MD, MSc; Instituto Nacional De Neurologia Y Neurocirugia; México City, México
Tatyana Simuni, MD; Northwestern University; Chicago, IL, USA
Claire Henchcliffe, MD, DPhil; University of California, Irvine; Orange, CA, USA
The four-part MDS-PAS New and Emerging Therapies in Parkinson’s Disease and other Movement Disorders will provide up-to-date knowledge about therapies in Parkinson’s disease, Huntington disease and tardive dyskinesia that represent an innovation in clinical care or, although still in clinical trial phase, may change dramatically clinical practice in the near future. The series will highlight topics on: “New therapies of tardive dyskinesia”, “Gene-based therapies in Huntington's disease”, “New therapies of OFF time in Parkinson's disease” and “Investigational disease-modifying therapies in Parkinson’s disease”.
Please note the webinar “New therapies for OFF time in Parkinson’s Disease” will be offered in both Spanish and English.
Participants are encouraged to attend all sessions but sessions are not dependent.
New therapies of tardive dyskinesia (Wednesday, March 10, 2021)
The treatment of tardive dyskinesia and other tardive syndromes has been limited to few medications (i.e., amantadine, anticholinergics, benzodiazepines) with scant evidence for sustained and meaningful benefit. The emergence of VMAT2 inhibitors radically changed the treatment landscape of tardive dyskinesia and other tardive syndromes. It has allowed for a re-focused attention on the need to better understand the disease in all its aspects and to improve outcomes. This webinar will provide a brief overview of management of tardive dyskinesia and other tardive syndromes and review the science and therapeutic evidence of these recently released novel agents.
- Summarize the key pathophysiological understanding of tardive dyskinesia and other tardive syndromes and therapies other than VMAT2 inhibitors
- Describe the mechanism of action of VMAT2 inhibitors
- Explain the pivotal clinical trials that resulted in approval of these compounds
- Identify the evidence of effectiveness and safety profile of VMAT2 inhibitors for the different tardive syndromes
Gene-based therapies in Huntington's disease (Wednesday, March 24, 2021)
The discovery of the Huntington disease (HD) gene in 1993 brought with it a promise of treatments that would significantly impact the expression or progression of the disease. Almost three decades later, gene-based therapies are finally on the horizon. Years of laboratory in vitro and in vivo experiments have yielded key basic science insights. A resultant variety of approaches to silence the pathogenic gene are currently undergoing human trials. This webinar will cover the mechanisms of action and experimental basis of such clinical trials as well as their current state of development and early findings, including allele specific and non-specific treatments broadly divided in those of intrathecal and intra-cranial administration.
- Describe the mechanisms of action of the different gene-based therapies for Huntington’s disease
- Illustrate the different approaches of these therapies, their advantages and challenges
- Evaluate the current state of development of on-going clinical trials
New therapies of OFF time in Parkinson's disease – Presented in both Spanish and English (Wednesday, April 7, 2021)
Off time in its various presentations represent some of the most common complications of chronic levodopa therapy. This important clinical problem has spawned numerous clinical trials over the past three decades. Recently, there have been new additions to the treatment of off time, some of them novel in their route of delivery, and each responding to specific clinical scenarios. This webinar will cover these new treatment modalities with emphasis on their practical application and will be available in Spanish and English.
- Review current strategies and gaps in treatment of OFF-time
- Enumerate the new therapies in Parkinson disease targeting “Off-time”
- Compare the pivotal clinical trials including their effectiveness and side effect profile
Investigational disease-modifying therapies in Parkinson’s Disease (Wednesday, April 21, 2021)
A number of clinical trials are presently in different stages of development with the aim of disease modification of Parkinson’s disease (PD). They are based on targeting a variety of pathophysiological pathways and grounded on experimental evidence of potential benefit. This webinar will highlight distinct therapeutic areas of disease modification in PD that are under active investigation.
- Describe current key trial trials of disease modification and the associated pathways of disease modification
- Apply the lessons learned from unsuccessful trials
- Outline future directions in the field
All sessions will hold a live Q&A session with the experts after the lectures. Participants will have an opportunity to submit questions during the live Q&A session.
Movement disorders specialists, general neurologists, primary care physician, nurse practitioner, physician assistant, fellows: movement disorders, clinical/research, geriatrics/psychiatry; Resident: Neurology, psychiatry/geriatrics
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement:
The International Parkinson and Movement Disorder Society designates this activity for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation.
Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.
Content Validity Statement:
All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.
Disclosure of Financial Relationships & Resolution:
All individuals in control of content for this activity are required to disclose all financial relationships with ineligible companies (as defined by the ACCME) over the last 24 months. Disclosure information will be available on the course website. All relevant financial relationships will be mitigated in advance of this program.